Claims for Patent: 4,760,075

Summary for Patent: 4,760,075

Title:	N-thiazolylmethylthioalkyl-N-alkyl-amidines and related compounds
Abstract:	N-alkyl-N'-(2-aminomethyl-4-thiazolylmethylthio)alkyl guanidines, thioureas, ethenediamines and related compounds, H2 -receptor antagonists, useful in inhibiting gastric acid secretion in mammals.
Inventor(s):	Richard P. Pioch
Assignee:	Eli Lilly and Co
Application Number:	US06/814,274
Patent Claims:	1. A compound of the formula ##STR35## wherein R1 represents hydrogen, methyl, ethyl, benzyl or benzoyl; R2 represents methyl or ethyl; or R1 and R2 taken together with the nitrogen atom to which they are attached, form a piperidino, pyrrolidino or morpholino radical;R3 is hydrogen or methyl; Z is O, S or CH2 ; n is 2 or 3 when Z is O or S and n is 1, 2 or 3 when Z is CH2 ; Q is ##STR36## wherein A is N-CN, N-NO2, CH-NO2, S, N-SO2 -aryl, N-SO2 -methyl or N-CO-NH2, wherein aryl is phenyl or tolyl; and B is NHR, wherein R is methyl, ethyl, cyclopropyl or (2-hydroxy)ethyl; or B is YR4, wherein Y is oxygen or sulfur and R4 is (C1 -C3 alkyl, -CH2 -(C2 -C4) alkenyl or benzyl; provided that when Q is ##STR37## B is NHR or O--(C1 -C2)-alkyl; and acid addition salts thereof. 2. A thiazole derivative as claimed in claim 1 wherein R1 is hydrogen, methyl, ethyl, benzyl or benzoyl; R2 is methyl or ethyl; or R1 and R2 taken together with the adjacent nitrogen atom represent a piperidino, pyrrolidino or morpholino group; R3 is hydrogen or methyl; A is N-CN, N--NO2, CH-NO2, S, N-SO2 --aryl, N-SO2 --methyl or N-CO-NH2, where aryl is phenyl or tolyl; B is NHR or YR4 wherein R is methyl, ethyl, cyclopropyl or 2-(hydroxy)ethyl and R4 is (C1 -C3)alkyl; provided that when B is YR4, Q is C═A; or a pharmaceutically-acceptable, acid addition salt thereof. 3. A thiazole derivative as claimed in claim 1, wherein Z is sulfur. 4. A thiazole derivative as claimed in claim 1 wherein n is 2. 5. A thiazole derivative as claimed in claim 1, wherein R3 is hydrogen. 6. A thiazole derivative as claimed in claim 1, wherein R1 and R2 are methyl. 7. A thiazole derivative as claimed in claim 1, wherein A is NCN or CHNO2. 8. A thiazole derivative as claimed in claim 1, wherein B is NHR where R is methyl or ethyl. 9. A thiazole derivative as claimed in claim 8, wherein B is methylamino. 10. A compound according to claim 1 in which R3 is H, R1 is H, methyl or ethyl, R2 is methyl or ehtyl, Z is S, Q is ##STR38## A is N-CN, N-NO2 or CH-NO2, B is NHR, and R is methyl or ethyl. 11. A compound according to claim 10, said compund being N-methyl-N'-2-(2-methylaminomethyl-4-thiazolylmethylthio)ethyl 2-nitro-1,1-ethenediamine. 12. A compound according to claim 10, said compound being N-methyl-N'-2-(2-dimethylaminomethyyl-4-thiazoIylmethylthio)ethyl-N"-cyanoguanidine. 13. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect, comprising per dosage unit an antisecretorially-effective amount of a compound of claim 1 wherein B is NHR plus one or more pharmaceutical excipients. 14. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect, comprising per dosage unit an antisecretorially-effective amount of a compound of claim 10 plus one or more pharm.aceutical excipients. 15. A pharmaceutical formulation according to claim 13 containing from 50-80 mg. of active drug per dosage unit. 16. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect, comprising per dosage unit an antisecretorially-effective amount of a compound according to claim 2 plus one or more pharmaceutical excipients. 17. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal, whose gastric acid secretion is excessive and who is in need of treatment, an antisecretorially effective amount of a compound according to claim 1. 18. A method according to claim 17 in which from 140-350 mg. of drug per day are administered orally to humans. 19. A method according to claim 18 in which the oral daily dose is from 2-5 mg./kg. of mammalian body weight. 20. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal, whose gastric acid secretion is excessive and who is in need of treatment, an antisecretorially effective amount of a compound according to claim 2. 21. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal, whose gastric acid secretion is excessive and who is in need of treatment, an antisecretorially effective amount of a compound according to claim 10. 22. A method according to claim 17 in which the antisecretory drug is administerd orally. 23. A method according to claim 17 in which the antisecretory drug is administered parenterally. 24. A method of inhibiting H2 histamine receptors which comprises administering to an animal an amount effective to inhibit said receptors of a compound according to claim 1 wherein B is NHR.